BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 33675543)

  • 1. Clinical value of 2D speckle tracking imaging in evaluating the effect of percutaneous intramyocardial septal radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy.
    Qian D; Zhou X; Liu H; Cao L
    J Clin Ultrasound; 2021 Jul; 49(6):554-562. PubMed ID: 33675543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety of transthoracic echocardiography-guided percutaneous intramyocardial septal radiofrequency ablation for the treatment of patients with obstructive hypertrophic cardiomyopathy].
    Liu LW; Zuo L; Zhou MY; Li J; Zhou XD; He GB; Zhang J; Zhang JZ; Liu B; Yang J; Xu B
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Apr; 47(4):284-290. PubMed ID: 31060187
    [No Abstract]   [Full Text] [Related]  

  • 3. Reduction of left ventricular mass, left atrial size, and N-terminal pro-B-type natriuretic peptide level following alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.
    Dąbrowski M; Kukuła K; Kłopotowski M; Bekta P; Śpiewak M; Mazurkiewicz Ł; Tyczyński P; Orczykowski M; Parma R; Witkowski A
    Kardiol Pol; 2019; 77(2):181-189. PubMed ID: 30566209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy.
    Liu L; Li J; Zuo L; Zhang J; Zhou M; Xu B; Hahn RT; Leon MB; Hsi DH; Ge J; Zhou X; Zhang J; Ge S; Xiong L
    J Am Coll Cardiol; 2018 Oct; 72(16):1898-1909. PubMed ID: 30309466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left ventricular longitudinal systolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a long-term follow-up study focused on speckle tracking echocardiography.
    Sommer A; Poulsen SH; Mogensen J; Thuesen L; Egeblad H
    Eur J Echocardiogr; 2010 Dec; 11(10):883-8. PubMed ID: 20667848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocardial mechanics of percutaneous intramyocardial septal radiofrequency ablation.
    Li J; Zhang J; Shi Y; Sievert H; Taub CC; Bertog S; Ta S; Changhui L; Senser E; Wang J; Hu R; Huang J; Ruan F; Han Y; Li X; Wang B; Zhao X; Liu J; Hsi DH; Liu L
    Heart; 2023 Jan; 109(4):289-296. PubMed ID: 36270787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short time effects of two radiofrequency ablation methods on hypertrophic obstructive cardiomyopathy.
    He YG; Dong Y; Yang SH; Yang F; Yin JL; Zhao HQ; Zhao YJ
    Clin Cardiol; 2024 Feb; 47(3):e24217. PubMed ID: 38439605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy.
    Zhou M; Ta S; Hahn RT; Hsi DH; Leon MB; Hu R; Zhang J; Zuo L; Li J; Wang J; Wang B; Zhu X; Liu J; Han Y; Li X; Xu B; Zhang L; Hou L; Han C; Liu J; Liu L
    JAMA Cardiol; 2022 May; 7(5):529-538. PubMed ID: 35353129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide level in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction.
    Kim SW; Park SW; Lim SH; Kwon SU; Choi YJ; Park MK; Lee SC; Lee SH; Park JE; Jeon ES
    Clin Cardiol; 2006 Apr; 29(4):155-60. PubMed ID: 16649724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percutaneous intramyocardial septal radiofrequency ablation after 5-year follow-up.
    Ta S; Li J; Hsi DH; Hu R; Lei C; Shan B; Li W; Wang J; Wang B; Kang N; Li X; Liu J; Qi C; Huang J; Han Y; Ruan F; Zhang J; Liu L
    Heart; 2024 May; 110(11):792-799. PubMed ID: 38388470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peak systolic longitudinal strain of the lateral left ventricular wall improves after septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: a follow-up study using speckle tracking echocardiography.
    Faber L; Prinz C; Welge D; Hering D; Butz T; Oldenburg O; Bogunovic N; Horstkotte D
    Int J Cardiovasc Imaging; 2011 Mar; 27(3):325-33. PubMed ID: 20694748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial perfusion improvement and mechanism after percutaneous intramyocardial septal radiofrequency ablation in obstructive hypertrophic cardiomyopathy: a study of myocardial contrast echocardiography.
    Yao L; Ta S; Wang J; Han C; Lei C; Li W; Li J; Wang B; Zhao X; Liu L
    Int J Cardiovasc Imaging; 2024 May; ():. PubMed ID: 38709352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Septal reduction therapy using nonalcohol agent in hypertrophic obstructive cardiomyopathy: Single center experience.
    Asil S; Kaya B; Canpolat U; Yorgun H; Şahiner L; Çöteli C; Arat A; Aytemir K
    Catheter Cardiovasc Interv; 2018 Sep; 92(3):557-565. PubMed ID: 29205803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyssynchronization reduces dynamic obstruction without affecting systolic function in patients with hypertrophic obstructive cardiomyopathy: a pilot study.
    Giraldeau G; Duchateau N; Bijnens B; Gabrielli L; Penela D; Evertz R; Mont L; Brugada J; Berruezo A; Sitges M
    Int J Cardiovasc Imaging; 2016 Aug; 32(8):1179-88. PubMed ID: 27146905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.
    Brito D; Matias JS; Sargento L; Cabral MJ; Madeira HC
    Rev Port Cardiol; 2004 Dec; 23(12):1557-82. PubMed ID: 15732658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous trans-apex intra-septal radiofrequency ablation of hypertrophic cardiomyopathy.
    Zuo L; Sun C; Yang J; Liu B; Zhou M; Guo R; Yu S; Ge J; Xiong L; Liu L
    Minim Invasive Ther Allied Technol; 2018 Apr; 27(2):97-100. PubMed ID: 28949276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum cardiac troponin I is related to increased left ventricular wall thickness, left ventricular dysfunction, and male gender in hypertrophic cardiomyopathy.
    Kubo T; Kitaoka H; Okawa M; Yamanaka S; Hirota T; Hoshikawa E; Hayato K; Yamasaki N; Matsumura Y; Yasuda N; Sugiura T; Doi YL
    Clin Cardiol; 2010 Feb; 33(2):E1-7. PubMed ID: 20043329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early remodelling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy.
    Veselka J; Honek T
    Int J Cardiol; 2003 Mar; 88(1):27-32. PubMed ID: 12659981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy.
    Nagueh SF; Lakkis NM; Middleton KJ; Killip D; Zoghbi WA; Quiñones MA; Spencer WH
    J Am Coll Cardiol; 1999 Oct; 34(4):1123-8. PubMed ID: 10520801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy.
    Shelke AB; Menon R; Kapadiya A; Yalagudri S; Saggu D; Nair S; Narasimhan C
    Indian Heart J; 2016; 68(5):618-623. PubMed ID: 27773399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.